Literature DB >> 26550190

Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.

Yang Liu1, Xiaobin Gu1, Qunying Lin2, Tian Tian1, Lijuan Shao3, Chao Yuan1, Bo Zhang4, Kexing Fan4.   

Abstract

BACKGROUNDS: Non-small cell lung cancer (NSCLC) is one of the most common malignancies with a high mortality level. Recently, a variety of studies explored the role of osteopontin (OPN) expression in the prognosis of NSCLC, but the results were controversial.
METHODS: We performed a meta-analysis of eligible studies to evaluate the prognostic significance of OPN expression in NSCLC patients. In order to assess the association between OPN and OS and DFS/PFS, hazard ratio (HR) with 95% confidence interval (CI) was calculated.
RESULTS: A total of ten studies comprising 1420 patients were included in the meta-analysis. The summary results indicated that high OPN expression was a poor predictor for OS (HR = 2.19, 95% CI: 1.6-2.98), and DFS/PFS (HR = 2, 95% CI: 1.66-2.41). Subgroup analysis revealed that high OPN expression was a negative prognostic marker for OS and DFS/PFS regardless of ethnicity background, treatment and OPN detection method.
CONCLUSION: Our results showed that increased OPN expression significantly correlated with poor OS and DPS/PFS in NSCLC patients.

Entities:  

Keywords:  Non-small cell lung cancer; biomarker; osteopontin; prognosis

Year:  2015        PMID: 26550190      PMCID: PMC4612875     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.

Authors:  Tao Zhang; Dong-ming Zhang; Da Zhao; Xiao-ming Hou; Tian-ning Yang
Journal:  J BUON       Date:  2014 Jul-Sep       Impact factor: 2.533

3.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

Review 6.  The cancer biomarker osteopontin: combination with other markers.

Authors:  Georg F Weber
Journal:  Cancer Genomics Proteomics       Date:  2011 Nov-Dec       Impact factor: 4.069

Review 7.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

8.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

9.  Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.

Authors:  Bing-Sheng Sun; Yue Li; Zhen-Fa Zhang; Jian You; Chang-Li Wang
Journal:  Ann Thorac Surg       Date:  2013-10-03       Impact factor: 4.330

10.  Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis.

Authors:  S Denda; L F Reichardt; U Müller
Journal:  Mol Biol Cell       Date:  1998-06       Impact factor: 4.138

View more
  2 in total

1.  Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.

Authors:  Federico Carbone; Francesco Grossi; Aldo Bonaventura; Alessandra Vecchié; Silvia Minetti; Nicholas Bardi; Edoardo Elia; Anna Maria Ansaldo; Daniele Ferrara; Erika Rijavec; Maria Giovanna Dal Bello; Federica Biello; Giovanni Rossi; Marco Tagliamento; Angela Alama; Simona Coco; Paolo Spallarossa; Franco Dallegri; Carlo Genova; Fabrizio Montecucco
Journal:  Clin Exp Metastasis       Date:  2019-08-02       Impact factor: 5.150

2.  Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis.

Authors:  Chengcheng Hao; Zhiyan Wang; Yanan Gu; Wen G Jiang; Shan Cheng
Journal:  Biomed Res Int       Date:  2016-07-04       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.